From January 1, 2024 to March 31, 2024, the company has repurchased 239,555 shares, representing 0.003912% for CNY 10 million. With this, the company has completed the repurchase of 14,351,878 shares, representing 0.23% for CNY 634.67 million under the buyback announced on May 15, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
46.16 CNY | -0.04% | +10.27% | +2.06% |
Apr. 26 | Hengrui Pharma Gets Nod to Trial Insulin Aspart Injection; Shares Up 3% | MT |
Apr. 17 | Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.06% | 40.55B | |
+29.68% | 681B | |
+20.93% | 556B | |
-4.35% | 361B | |
+17.65% | 325B | |
+3.77% | 285B | |
+13.77% | 235B | |
+4.62% | 199B | |
-12.47% | 189B | |
-3.79% | 157B |
- Stock Market
- Equities
- 600276 Stock
- News Jiangsu Hengrui Medicine Co., Ltd.
- Tranche Update on Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023.